CAPR10:02 AMCapricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophycapricor.com
CAPR9:05 AMCapricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual ConferencePresentation / Abstract • Phase 3Late-breaking presentation Sat, Jun 27, 2026capricor.com
CAPR4:05 PMCapricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updatecapricor.com
CAPR5:00 PMCapricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophycapricor.com
CAPR4:05 PMCapricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12capricor.com
CAPR9:00 AMCapricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual MeetingTrial Results • Phase 3capricor.com